Targeting mycobacterial transpeptidases: evaluating the roles of Ldt and PBP inhibition in suppressing Mycobacterium smegmatis
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.00126-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Mariska de Munnik und 3 weiteren Autor:innen. Beteiligte Einrichtung: Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute of Antimicrobial Research, University of Oxford, Oxford, United…. Hauptthemen laut MEDLINE: Mycobacterium smegmatis, Penicillin-Binding Proteins, Peptidyl Transferases, beta-Lactams. Die Arbeit nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biotechnology and Biological Sciences Research Council, Wellcome Trust, Tres Cantos Open Lab Foundation.
Abstract (Originalsprache)
β-lactams demonstrate promising in vitro activity against Mycobacterium species and are being explored for tuberculosis treatment; however, evidence of their in vivo efficacy versus Mycobacterium tuberculosis remains limited. To achieve broad clinically relevant potency, optimization of the classical β-lactam scaffolds or development of new or non-β-lactam inhibitors for mycobacterial transpeptidases is likely required. In mycobacteria, potential targets of β-lactams include l,d -transpeptidases (Ldts) and penicillin-binding proteins (PBPs). Reports suggest that dual inhibition of Ldts and PBPs may be necessary to achieve effective anti-mycobacterial activity, yet the specific contributions of Ldt and PBP inhibition to the β-lactam antibacterial mechanisms are poorly understood. We used fluorogenic substrate mimics to investigate the effects of β-lactams and reported Ldt Mt2 inhibitors on Mycobacterium smegmatis ( Msm ), assessing their impacts on Ldt and PBP transpeptidase activities in living cells. The results reveal a statistically significant correlation between both Ldt and PBP inhibition and Msm growth suppression; under the tested conditions, a stronger correlation between Ldt inhibition and Msm growth suppression was observed. Notably, apparent inhibition of both PBPs and Ldts was observed with all active inhibitors, though β-lactams manifest increased potency of PBP inhibition. The combination of the β-lactams meropenem and faropenem with selected Ldt Mt2 inhibitors manifested an additive inhibitory effect against Msm . Our results highlight the importance of further optimizing β-lactam efficacy versus mycobacterial PBPs and Ldt transpeptidases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute of Antimicrobial Research, University of Oxford, Oxford, United Kingdom.
- Diamond Light Source, Diamond House, Harwell Science and Innovation Campus, Didcot, United Kingdom.
ORCID-Profile: Mariska de Munnik, Patrick Rabe, Christopher J Schofield
Förderung
- Biotechnology and Biological Sciences Research Council
- Wellcome Trust
- Tres Cantos Open Lab Foundation
Zitieren
APA
de Munnik, M., Calvopiña, K., Rabe, P., & Schofield, C. J. (2025). Targeting mycobacterial transpeptidases: evaluating the roles of Ldt and PBP inhibition in suppressing Mycobacterium smegmatis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00126-25
Vancouver
de Munnik M, Calvopiña K, Rabe P, Schofield CJ. Targeting mycobacterial transpeptidases: evaluating the roles of Ldt and PBP inhibition in suppressing Mycobacterium smegmatis. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00126-25
BibTeX
@article{deMunnik2025,
author = {de Munnik, Mariska and Calvopiña, Karina and Rabe, Patrick and Schofield, Christopher J},
title = {Targeting mycobacterial transpeptidases: evaluating the roles of Ldt and PBP inhibition in suppressing Mycobacterium smegmatis},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.00126-25}
}
EUVIMED